Infantile hemangiomas, complications and treatments

Semin Cutan Med Surg. 2016 Sep;35(3):108-16. doi: 10.12788/j.sder.2016.050.

Abstract

Infantile hemangiomas (IHs) are the most common vascular tumors of infancy. While the majority regress without the need for intervention, approximately 10%, often site dependent, can cause serious complications and require treatment. IH complications can be categorized as life threatening, obstructive, ulcerative or disfiguring. Life threatening complications include airway and hepatic IHs. Functional complications obstructing vital structures or impairing function include periocular, nasal, labial, parotid, auricular, and breast IHs. Local complications arise from ulceration or those in cosmetically sensitive areas. Therapeutic options for complicated IHs include pharmacologic (topical or systemic), surgical, or laser interventions. Topical agents are best employed for small, superficial, and localized IHs; while systemic therapy is reserved for larger IHs and those with more aggressive growth characteristics with propranolol as first-line therapy.

Keywords: airway IH; auricular IH; breast IH; infantile hemangiomas; lip IH; multiple cutaneous hemangiomas; nasal IH; parotid IH; periocular IH; propranolol; timolol; ulcerated IH.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adrenergic beta-Antagonists / therapeutic use
  • Airway Obstruction / etiology
  • Airway Obstruction / therapy
  • Drug Therapy, Combination
  • Esthetics
  • Facial Neoplasms / complications
  • Facial Neoplasms / therapy
  • Hemangioma / complications*
  • Hemangioma / therapy*
  • Humans
  • Infant
  • Laser Therapy
  • Propranolol / therapeutic use
  • Skin Neoplasms / complications*
  • Skin Neoplasms / therapy*
  • Skin Ulcer / etiology
  • Skin Ulcer / therapy
  • Timolol / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-Antagonists
  • Timolol
  • Propranolol